Listen on Causes or Cures:
GLP-1 medications such as semaglutide (Wegovy, Ozempic) and tirzepatide have rapidly become some of the most widely discussed drugs in modern medicine. Much of the attention has focused on how well they work while people are taking them.
But an important question has been quietly lingering in the background:
What happens after you stop GLP-1 weight loss drugs?
A high percentage of people prescribed these medications stop taking them, so this is a really important question.
In this episode of the Causes or Cures Podcast, I spoke with Dr. Sam West, a researcher at the University of Oxford, about his work examining exactly that.
Because while these medications can produce significant weight loss during treatment, obesity is a chronic condition, and what happens after treatment stops may matter just as much as what happens during it.
The Question Researchers Are Starting to Ask
GLP-1 receptor agonists work in several ways. They influence appetite signaling in the brain, slow gastric emptying, and help people feel full sooner and longer. The result for many patients is meaningful weight loss and improvements in cardiometabolic health markers.
But medications only work while they’re being taken.
Dr. West and colleagues wanted to understand what happens when treatment is discontinued.
Do people maintain the weight loss?
Does the weight come back?
And what happens to things like blood pressure, blood sugar, and other cardiometabolic markers after the medication stops?
These questions are especially important as insurers, clinicians, and patients try to figure out whether these drugs are short-term tools or long-term treatments.
How Quickly Does Weight Return?
One of the key findings from the research is that weight regain after stopping GLP-1 medications is common.
That doesn’t mean every person regains all of the weight they lost. But on average, many people do see the weight return after discontinuing treatment.
This is not entirely surprising.
The biological mechanisms that drive weight gain—hormonal signaling, appetite regulation, energy balance—don’t disappear simply because weight loss occurred during treatment.
When the medication is removed, those underlying systems may gradually reassert themselves.
In some ways, Dr. West explains, this pattern is similar to what we see after many weight-loss interventions, including behavioral programs.
Weight loss can be achieved. Weight maintenance is the harder part.
What Happens to Cardiometabolic Health?
The conversation also looked beyond weight itself.
GLP-1 medications have been associated with improvements in several cardiometabolic risk markers, including factors related to blood sugar regulation and cardiovascular health.
When treatment stops, those improvements also begin to shift.
This highlights something important:
The benefits of a therapy often track with the duration of the therapy itself.
This is not unique to obesity medications. It’s true across many areas of medicine.
When blood pressure medication stops, blood pressure often rises again. When cholesterol medication stops, cholesterol may increase again. Obesity treatment may follow a similar pattern.
What this Means in Practice
For patients, clinicians, and insurers, the implications are still being debated.
If the benefits of GLP-1 medications depend on continued treatment, several practical questions arise:
**Should these medications be viewed as long-term therapies only?
**How should insurers think about coverage and duration of treatment?
**What expectations should patients have about maintaining weight loss after stopping medication?
Dr. West emphasizes that understanding what happens after discontinuation helps provide real-world context for how these drugs may fit into long-term obesity management.
About the Guest
Dr. Sam West is a postdoctoral researcher with the Health Behaviours team in the Department of Primary Care Health Sciences at the University of Oxford.
He completed his PhD with the Nutritional Physiology Research Group at the University of Exeter, where his work focused on how dietary protein influences skeletal muscle metabolism after meals.
His current research examines how lifestyle factors and pharmaceutical treatments interact in the management of obesity and type 2 diabetes.
Listen to the Conversation:
You can listen to the full episode “What happens after you stop GLP-1 Weight Loss Drugs” on the Causes or Cures Podcast to hear the deeper discussion about:
**weight regain after GLP-1 medications
**cardiometabolic changes after treatment stops
**how these outcomes compare with lifestyle interventions
**what these findings may mean for long-term obesity treatment
**********************************************************************************************************
Other gems to check out in the blog:
How much does obesity impact your risk of severe infectious disease?